Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer

INTRODUCTION: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Therefore, we planned to develop a new combination che...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Shintaro, Kawamoto, Yasuyuki, Yuki, Satoshi, Harada, Kazuaki, Miyagishima, Takuto, Sogabe, Susumu, Dazai, Masayoshi, Sato, Atsushi, Ishiguro, Atsushi, Nakamura, Michio, Kajiura, Shinya, Takahashi, Yasuo, Tateyama, Miki, Hatanaka, Kazuteru, Tsuji, Yasushi, Sasaki, Takahide, Shindo, Yoshiaki, Kobayashi, Tomoe, Yokota, Isao, Sakamoto, Naoya, Sakata, Yuh, Komatsu, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086607/
https://www.ncbi.nlm.nih.gov/pubmed/35534074
http://dx.doi.org/10.1136/bmjopen-2021-048833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086607/
https://www.ncbi.nlm.nih.gov/pubmed/35534074
http://dx.doi.org/10.1136/bmjopen-2021-048833

Ejemplares similares